Clinical Management of Hypoactive Sexual Desire Disorder

Sheryl Kingsberg, PhD, IF; Stephanie Faubion, MD, FACP, NCMP, IF

Disclosures

Menopause. 2019;26(2):217-219. 

In This Article

Summary

Although HSDD has biopsychosocial etiologies, HCPs can accurately screen, diagnose, and treat this condition. Providers of midlife women's healthcare are uniquely positioned to identify and counsel patients with HSDD. Treatment options are psychotherapy, pharmacotherapy, or a combination. Treating symptomatic GSM, if present, may be helpful in addressing low sexual desire related to dyspareunia. There are no FDA-approved pharmacologic options for postmenopausal women. Off-label treatments most commonly include flibanserin and testosterone.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....